The above information was disclosed in a filing to the SEC. Some additional info was provided as follows:
The transaction reported was effected pursuant to a 10b-5 trading plan. The sales are being made in connection with Reporting Person's divorce settlement.
This transaction was executed in multiple trades at prices ranging from $1.59 to $1.69. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issu
er or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
To see this filing in its entirety, click here.
To receive a free e-mail notification whenever an insider of Neuralstem makes a similar move, sign up!
Other recent filings from the company include the following:
Notice of Exempt Offering of Securities, item 06b
- Oct. 31, 2014
Neuralstem: Entry Into A Material Definitive Agreement - Oct. 29, 2014
Current report, items 8.01 and 9.01 - Oct. 23, 2014
First Patient Treated In Neuralstem Phase I Spinal Cord Injury Stem Cell Trial Through The Uc San Diego Sanford Stem Cell Clinical Center - Oct. 9, 2014